poisar

Stock

Theravance Biopharma, Inc. TBPH

$17.04-0.03%

Overview

TBPH market data

Price History

TBPH price chart · 1M
O
17.06
H
17.10
L
17.03
C
17.04
Vol
32,472.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$17.06
Previous Close
$17.04
Day High
$17.10
Day Low
$17.03
52 Week High
$17.66
52 Week Low
$15.53
7 Day Return
+0.47%
30 Day Return
+0.86%
90 Day Return
+6.17%
1 Year Return
+2.28%
Daily Notional Volume
$553.2K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
7.67
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$2.06
Diluted earnings per share over the trailing twelve months.
Beta
0.19
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
104.3%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$13.08 – $21.03
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $878.5M · P/B 3.20 · P/S 8.00.

Company News

8 captured
8-K filing — Theravance Biopharma, Inc. (TBPH)SEC EDGAR · Aug 25, 2026, 8:52 PM
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M EstimateBenzinga · Aug 10, 2026, 12:35 PM
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026Globenewswire Inc · Jul 16, 2026, 11:00 AM
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17Benzinga · Jul 7, 2026, 11:50 AM
Jones Trading Downgrades Theravance Biopharma to HoldBenzinga · Jun 29, 2026, 3:45 PM
BTIG Downgrades Theravance Biopharma to NeutralBenzinga · Jun 29, 2026, 3:35 PM
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionBenzinga · Jun 29, 2026, 1:25 PM
Zymeworks to Acquire Theravance Biopharma, Inc.Globenewswire Inc · Jun 29, 2026, 11:00 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock